Therapeutic outcomes of the LHRH antagonists-Reference-Cited by-同舟云学术

Therapeutic outcomes of the LHRH antagonists

Published:2017-09-03 Issue:5 Volume:17 Page:481-488
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Dellis Athanasios¹²,Papatsoris Athanasios¹

Affiliation:

1. University Department of Urology, Sismanglio General Hospital, Athens, Greece

2. University Department of Surgery, Areteion Hospital, Athens, Greece

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2017.1375855

Reference53 articles.

1. Receptors for Luteinizing Hormone-Releasing Hormone (LHRH) in Dunning R3327 Prostate Cancers and Rat Anterior Pituitaries after Treatment with a Sustained Delivery System of LHRH Antagonist SB-75*

2. Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH Analogues

3. US Food and Drug Administration. FDA approves drug for patients with advanced prostate cancer [online]. [cited 2009 Jan 5]. Available from: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01935.html

4. Ferring Pharmaceuticals. European Commission grants Ferring Pharmaceuticals approval of Firmagon (degarelix) for treatment of prostate cancer [online]. cited 2009 Mar 6. Available from: http://www.ferring.com

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Terapias emergentes en el tratamiento médico de los miomas uterinos;Medicina Clínica;2023-10

2. Comparative analysis of real-world data of frequent treatment sequences in metastatic prostate cancer;Current Urology;2023-06-28

3. Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study;BMC Medicine;2023-04-03

4. Actualización sobre las posibilidades de tratamiento médico hormonal para el sangrado menstrual abundante;Clínica e Investigación en Ginecología y Obstetricia;2023-01

5. Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study;Investigative and Clinical Urology;2023